Lilly is developing an experimental amylin drug aimed at aiding weight loss and diabetes management, similar to GLP-1 medications. Initial findings suggest that combining this drug with Zepbound could lead to weight loss of up to 23%. However, this combination also resulted in a higher incidence of side effects compared to Zepbound alone.
As Lilly advances its amylin drug, stakeholders should monitor ongoing trials for safety profiles and efficacy. The combination with Zepbound could reshape treatment protocols for obesity and diabetes, but the heightened side effects warrant close scrutiny in future studies.